Li Ningning, Gao Liwei, Bai Chunmei, Zhao Lin, Shao Yajuan
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Radiation Oncology, China-Japan Friendship Hospital, Beijing, China.
Front Oncol. 2023 Jun 5;13:1167213. doi: 10.3389/fonc.2023.1167213. eCollection 2023.
Studies have demonstrated a close association between connective tissue diseases (CTDs) and lung cancer (LC). Evidence supports that poor survival may be associated with the presence of CTDs in patients with LC.
This retrospective cohort study investigated 29 patients with LC with CTDs, and 116 patients with LC without CTDs were enrolled as case-matched control cohorts. Medical records, therapeutic efficacy of cancer, and outcomes were analyzed.
The median duration from the diagnosis of CTDs to LC was 17 years. The Eastern Cooperative Oncology Group (ECOG) performance score for LC-CTD patients was worse than that for matched non-CTD LC patients. The median progression-free survival (mPFS) and overall survival (mOS) of first-line chemotherapy did not differ between patients with lung adenocarcinoma (AC) with and without CTDs. A significant difference was observed in mPFS [4 months vs. 17 months; hazard ratio (HR), 9.987; = 0.004] and mOS (6 months vs. 35 months; HR, 26.009; 0.001) of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment between patients with AC with and without CTDs. The presence of CTD, sex, ECOG performance status, and tumor-node-metastasis clinical stage were the independent prognostic factors in all patients with non-small cell LC (NSCLC). ECOG performance status was determined to be an independent prognostic factor in patients with LC-CTD. In patients with NSCLC with CTD (n = 26), sex (male) and worse ECOG score were the independent poor prognostic factors.
CTDs were associated with poor survival in patients with LC. The therapeutic efficacy of first-line EGFR-TKI therapy was significantly worse in patients with lung AC with CTDs than in those without CTDs. ECOG performance status was determined as an independent prognostic factor for patients with LC and CTDs.
研究表明结缔组织病（CTD）与肺癌（LC）之间存在密切关联。有证据支持LC患者生存较差可能与CTD的存在有关。
这项回顾性队列研究调查了29例合并CTD的LC患者，并纳入116例无CTD的LC患者作为病例匹配对照队列。分析病历、癌症治疗疗效和结局。
从CTD诊断到LC的中位时间为17年。LC-CTD患者的东部肿瘤协作组（ECOG）体能状态评分比匹配的非CTD LC患者差。肺腺癌（AC）合并和不合并CTD患者一线化疗的中位无进展生存期（mPFS）和总生存期（mOS）无差异。AC合并和不合并CTD患者一线表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗的mPFS[4个月对17个月；风险比（HR），9.987；P = 0.004]和mOS（6个月对35个月；HR，26.009；P = 0.001）存在显著差异。CTD的存在、性别、ECOG体能状态和肿瘤-淋巴结-转移临床分期是所有非小细胞肺癌（NSCLC）患者的独立预后因素。ECOG体能状态被确定为LC-CTD患者的独立预后因素。在合并CTD的NSCLC患者（n = 26）中，性别（男性）和较差的ECOG评分是独立的不良预后因素。
CTD与LC患者生存较差有关。合并CTD的肺AC患者一线EGFR-TKI治疗的疗效明显低于无CTD的患者。ECOG体能状态被确定为LC和CTD患者的独立预后因素。
